Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

MinervaX Announces Award of 4.4 Million Euro in Investment from Novo Holdings REPAIR Impact Fund and Sunstone Capital for Further Clinical Development of the Company’s Vaccine Against Group B Streptococcus (GBS)

b3cnewswireJanuary 22, 2019

Tag: MinervaX , Antimicrobial resistance , GBS , Vaccine

PharmaSources Customer Service